跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
許 銘能
助理教授
藥學系
電話
(02) 2826-7985
電子郵件
mnshiu
nycu.edu
tw
h-index
h10-index
h5-index
605
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
131
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
56
引文
3
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2000
2024
每年研究成果
概覽
指紋
網路
研究成果
(32)
類似的個人檔案
(6)
指紋
查看啟用 Ming-Neng Shiu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Alcohol
12%
Antibiotic Use
8%
Behavioral Intention
8%
Betel Quid
11%
Cardiovascular Risk
8%
Chronic Disease
9%
Combined Test
17%
Community-based
17%
Confidence Interval
11%
Cost-effectiveness Analysis
17%
Di-(2-ethylhexyl) Phthalate
8%
Disease Screening
9%
Emergency Department
17%
Emergency Department Length of Stay
17%
Emergency Room
13%
Enterovirus
8%
Evaluation of Care
8%
Fecal Occult Blood Test
8%
Home Care
9%
Integrated Screening
12%
Length of Stay
17%
Leukoplakia
26%
Long-term Care Facilities
9%
Malignant Transformation
28%
National Cohort Study
17%
National Health Insurance
15%
Natural History of Disease
16%
Nicotine Replacement Therapy
8%
Odds Ratio
12%
Older Patients
10%
Older Smokers
8%
Oral Cancer
19%
Patients with Hypertension
10%
Population-based
17%
Preventive Medicine
8%
Psoriasis
25%
Psoriatic Arthritis
10%
Public Health
13%
Quality of Care
14%
Regulatory Science
8%
Risk Assessment
8%
Risk Factors
17%
Screening Program
14%
Smoking Cessation
16%
Smoking Cessation Intervention
8%
Taiwan
100%
Tobacco Control
9%
Transition Rates
10%
Unresectable Hepatocellular Carcinoma
8%
Varenicline
17%
Nursing and Health Professions
Antibiotic Therapy
8%
Avascular Necrosis
8%
Bevacizumab
8%
Cardiovascular Disease
6%
Cardiovascular Risk
8%
Care Group
7%
Chronic Disease
6%
Cohort Analysis
8%
Common Cold
5%
Comorbidity
5%
Compliance
8%
Confidence Interval
7%
Cost Effectiveness Analysis
8%
Cross-Sectional Study
11%
Diastolic Blood Pressure
8%
Diseases
20%
Emergency Ward
17%
Home Care
12%
Hormonal Therapy
8%
Hospital
9%
Immigrant Woman
8%
Institutional Care
7%
Length of Stay
17%
Leukoplakia
8%
Liver Cell Carcinoma
8%
Logistic Regression Analysis
5%
Long Term Care
9%
Malignant Transformation
8%
Mouth Carcinoma
8%
National Health Insurance
18%
Neoplasm
7%
Nicotine Replacement Therapy
8%
Nicotine Withdrawal
17%
Nurse
11%
Nutrition Policy
5%
Occult Blood
8%
Occult Blood Test
8%
Patient Referral
8%
Pressure Ulcer
5%
Prevalence
14%
Primary Medical Care
9%
Psoriasis
8%
Quality Adjusted Life Year
5%
Quality Control
8%
Screening
17%
Sorafenib
8%
Systolic Blood Pressure
6%
Tobacco Control
9%
Triage
9%
Varenicline
17%
Medicine and Dentistry
Antibiotic Therapy
8%
Antibiotics
8%
Avascular Necrosis
8%
Betel
5%
Biological Marker
8%
Cardiovascular Disease
7%
Cardiovascular Procedure
8%
Cardiovascular Risk
8%
Cardiovascular Surgery
8%
Care Group
8%
Cholangiocarcinoma
8%
Chronic Disease
5%
Cohort Analysis
17%
Common Cold
5%
Comorbidity
7%
Cost-Effectiveness Analysis
8%
Cross Sectional Study
10%
Decubitus
6%
Diastolic Blood Pressure
8%
Diseases
28%
Emergency Department
17%
Health Care Cost
8%
Health Information System
8%
Hormone Therapy
8%
Infection
5%
Leukoplakia
17%
Long-Term Care
8%
Malignant Transformation
17%
Mouth Carcinoma
8%
Neoplasm
7%
Nicotine Withdrawal
8%
Observational Study
8%
Oral Cancer
8%
Patient with Hypertension
10%
Pemigatinib
8%
Preventive Medicine
8%
Primary Health Care
8%
Psoriasis
17%
Public Health
12%
Screening
17%
Systolic Blood Pressure
6%
Targeted Therapy
8%
Triage
11%
Varenicline
8%
Womens Health
8%
